Not checkedNot checked for notices yet.

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial

Howard Gurney, Thomas Powles, Laurence Albiges and 16 more

ESMO Open · 2020

doi:10.1136/esmoopen-2020-001079 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

References15

15 more references, whose wording the paper’s licence keeps private.

Cited by papers we hold3

Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer · 2024
Cancer immunotherapy with immune checkpoint inhibitors (ICIs): potential, mechanisms of resistance, and strategies for reinvigorating T cell responsiveness when resistance is acquired · 2023
Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics · 2021

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.